A 29-year-old man with refractory ulcerative colitis has failed mesalamine, corticosteroids, and thiopurines. He requires hospitalization for severe bloody diarrhea (15 stools/day), abdominal pain, and fever. He is started on IV cyclosporine with improvement, then transitioned to oral cyclosporine. His gastroenterologist plans bridge therapy to infliximab. The patient develops a seizure on day 10 of cyclosporine therapy. His cyclosporine level is 320 ng/mL (target 200-400 ng/mL), magnesium is 1.2 mg/dL, cholesterol is 145 mg/dL. Evaluate the clinical presentation and synthesize the pathophysiology and management.
Q2
A 62-year-old liver transplant recipient on tacrolimus for 5 years presents with progressive confusion, ataxia, and visual disturbances over 2 weeks. MRI shows multifocal white matter lesions without mass effect or enhancement. CSF shows elevated protein (80 mg/dL), normal glucose, and 5 WBCs/μL. JC virus PCR in CSF is positive. CD4 count is 450 cells/μL. His tacrolimus level is therapeutic. Evaluate the clinical scenario and synthesize the optimal management strategy.
Q3
A 35-year-old pregnant woman at 8 weeks gestation with newly diagnosed severe lupus nephritis (Class IV) presents with nephrotic-range proteinuria, rising creatinine, and active urinary sediment. She desires to continue the pregnancy. Her rheumatologist needs to initiate immunosuppression urgently to prevent irreversible renal damage. Evaluate the treatment options and synthesize the optimal therapeutic approach.
Q4
A 50-year-old woman with rheumatoid arthritis refractory to methotrexate is being considered for rituximab therapy. Her labs show: positive rheumatoid factor, anti-CCP antibodies, normal CBC, and creatinine 1.1 mg/dL. Hepatitis panel shows: HBsAg negative, anti-HBs positive, anti-HBc positive, HBV DNA undetectable. Analyze her hepatitis status and determine the appropriate management before starting rituximab.
Q5
A 38-year-old kidney transplant recipient on sirolimus develops progressive dyspnea. CT chest shows bilateral interstitial infiltrates and small pleural effusions. Bronchoscopy with BAL shows lymphocytic inflammation without organisms. Pulmonary function tests show restrictive pattern with reduced DLCO. Cardiac evaluation is normal. Analyze the clinical presentation to determine the most likely diagnosis and management.
Q6
A 42-year-old heart transplant recipient on cyclosporine, azathioprine, and prednisone develops pancytopenia (WBC 2,000/μL, hemoglobin 8.5 g/dL, platelets 75,000/μL). He recently started allopurinol for gout. Bone marrow biopsy shows hypocellularity without malignant cells. His renal function is normal. Analyze the most likely cause of his pancytopenia and determine appropriate management.
Q7
A 28-year-old woman with systemic lupus erythematosus on chronic cyclophosphamide therapy presents with painless hematuria. Urinalysis shows 50-100 RBCs/hpf without casts. Urine cytology reveals atypical cells. Cystoscopy shows diffuse bladder wall erythema and hemorrhage. She has received cumulative cyclophosphamide dose of 60 grams over 3 years. Apply your knowledge to determine the most likely complication and appropriate next step.
Q8
A 55-year-old liver transplant recipient maintained on tacrolimus develops new-onset diabetes requiring insulin. He also has hypertension, chronic kidney disease (GFR 45 mL/min), and gingival hyperplasia. His current tacrolimus level is therapeutic. Apply pharmacologic principles to determine the most appropriate modification of his immunosuppressive regimen.
Q9
A 32-year-old man with newly diagnosed Crohn's disease has severe perianal fistulizing disease. His gastroenterologist plans to start infliximab therapy. The patient's PPD test is 12 mm induration, chest X-ray shows calcified granuloma in the right upper lobe, and interferon-gamma release assay is positive. He has no symptoms of active tuberculosis. Apply current guidelines to determine the appropriate management before starting infliximab.
Q10
A 45-year-old woman undergoes kidney transplantation and is started on tacrolimus, mycophenolate mofetil, and prednisone. Three weeks post-transplant, she develops tremors, elevated creatinine (2.8 mg/dL from baseline 1.2 mg/dL), and her tacrolimus trough level is 18 ng/mL (target 10-12 ng/mL). She recently started taking fluconazole for oral candidiasis. Apply your understanding of drug interactions to determine the most appropriate management.
Immunosuppressants US Medical PG Practice Questions and MCQs
Question 1: A 29-year-old man with refractory ulcerative colitis has failed mesalamine, corticosteroids, and thiopurines. He requires hospitalization for severe bloody diarrhea (15 stools/day), abdominal pain, and fever. He is started on IV cyclosporine with improvement, then transitioned to oral cyclosporine. His gastroenterologist plans bridge therapy to infliximab. The patient develops a seizure on day 10 of cyclosporine therapy. His cyclosporine level is 320 ng/mL (target 200-400 ng/mL), magnesium is 1.2 mg/dL, cholesterol is 145 mg/dL. Evaluate the clinical presentation and synthesize the pathophysiology and management.
A. Subtherapeutic cyclosporine level causing CNS infection; increase dose
B. Cyclosporine-induced posterior reversible encephalopathy syndrome; discontinue cyclosporine (Correct Answer)
C. Drug interaction with corticosteroids; discontinue steroids
D. Hypocholesterolemia increasing free cyclosporine; reduce dose
E. Hypomagnesemia-induced seizure; replace magnesium and continue cyclosporine
Explanation: ***Cyclosporine-induced posterior reversible encephalopathy syndrome; discontinue cyclosporine***
- **Cyclosporine** neurotoxicity can lead to **Posterior Reversible Encephalopathy Syndrome (PRES)**, which manifests as **seizures**, visual changes, and altered mental status regardless of "therapeutic" serum levels.
- Immediate **discontinuation** of the offending calcineurin inhibitor is the mandatory next step in management to prevent permanent neurological damage.
*Subtherapeutic cyclosporine level causing CNS infection; increase dose*
- The patient's level (320 ng/mL) is within the **target range** (200-400 ng/mL), making subtherapeutic dosing and subsequent infection unlikely.
- Increasing the dose would exacerbate the **neurotoxicity** and potentially lead to status epilepticus or irreversible brain injury.
*Drug interaction with corticosteroids; discontinue steroids*
- While corticosteroids can lower seizure thresholds at high doses, they are not the primary cause of sudden neurotoxicity in the setting of **calcineurin inhibitor** use.
- Discontinuing steroids abruptly in a patient with **refractory ulcerative colitis** could lead to a severe clinical flare or adrenal insufficiency.
*Hypocholesterolemia increasing free cyclosporine; reduce dose*
- Low serum **cholesterol** levels are a known risk factor for cyclosporine neurotoxicity because cholesterol carries the drug in the blood; however, simple dose reduction is insufficient.
- Once a **seizure** occurs (suggesting PRES), the drug must be stopped entirely rather than just adjusted, as the blood-brain barrier integrity is already compromised.
*Hypomagnesemia-induced seizure; replace magnesium and continue cyclosporine*
- **Hypomagnesemia** (1.2 mg/dL) lowers the seizure threshold and is a common side effect of cyclosporine, but it often acts as a cofactor for **PRES** rather than the sole cause.
- While **magnesium replacement** is necessary, continuing the cyclosporine while the patient is symptomatic is dangerous and clinically inappropriate.
Question 2: A 62-year-old liver transplant recipient on tacrolimus for 5 years presents with progressive confusion, ataxia, and visual disturbances over 2 weeks. MRI shows multifocal white matter lesions without mass effect or enhancement. CSF shows elevated protein (80 mg/dL), normal glucose, and 5 WBCs/μL. JC virus PCR in CSF is positive. CD4 count is 450 cells/μL. His tacrolimus level is therapeutic. Evaluate the clinical scenario and synthesize the optimal management strategy.
A. Discontinue tacrolimus completely and start high-dose steroids
B. Continue tacrolimus, start cidofovir for JC virus
C. Start plasmapheresis to remove tacrolimus, then restart lower dose
D. Switch from tacrolimus to cyclosporine to reduce neurotoxicity
E. Reduce tacrolimus to allow immune reconstitution, monitor closely (Correct Answer)
Explanation: ***Reduce tacrolimus to allow immune reconstitution, monitor closely***
- The patient presents with **Progressive Multifocal Leukoencephalopathy (PML)** due to **JC virus** reactivation, which requires reversing the underlying **immunosuppressed state**.
- Reducing **tacrolimus** is the standard management to allow for **immune reconstitution** to fight the virus, while balancing the risk of **graft rejection**.
*Discontinue tacrolimus completely and start high-dose steroids*
- Complete discontinuation of immunosuppression in a **liver transplant recipient** carries a high risk of **acute cellular rejection** and graft loss.
- **High-dose steroids** further suppress the immune system and would likely exacerbate the **JC viral replication** and clinical deterioration.
*Continue tacrolimus, start cidofovir for JC virus*
- Keeping the **calcineurin inhibitor** at therapeutic levels prevents the immune system from mounting a response against the **demyelinating infection**.
- Drugs like **cidofovir** have been studied for PML but have **not demonstrated clinical efficacy** and can be highly **nephrotoxic**.
*Start plasmapheresis to remove tacrolimus, then restart lower dose*
- **Plasmapheresis** is used to remove drugs like **natalizumab** in MS patients with PML to speed up immune recovery, but it is not indicated for removing **tacrolimus**.
- Tacrolimus is highly **protein-bound** and has a large **volume of distribution**, making it poorly cleared by apheresis techniques.
*Switch from tacrolimus to cyclosporine to reduce neurotoxicity*
- The symptoms are caused by a **JC virus infection (PML)** of the central nervous system, not by direct **tacrolimus neurotoxicity** (PRES).
- Both drugs are **calcineurin inhibitors** that cause equivalent levels of **T-cell suppression**, so switching would not address the viral progression.
Question 3: A 35-year-old pregnant woman at 8 weeks gestation with newly diagnosed severe lupus nephritis (Class IV) presents with nephrotic-range proteinuria, rising creatinine, and active urinary sediment. She desires to continue the pregnancy. Her rheumatologist needs to initiate immunosuppression urgently to prevent irreversible renal damage. Evaluate the treatment options and synthesize the optimal therapeutic approach.
A. Begin cyclophosphamide induction followed by azathioprine maintenance
B. Start high-dose prednisone and add mycophenolate mofetil
C. Recommend therapeutic abortion followed by standard cyclophosphamide protocol
D. Start rituximab as it has minimal placental transfer
E. Start prednisone and azathioprine, switch to mycophenolate postpartum (Correct Answer)
Explanation: ***Start prednisone and azathioprine, switch to mycophenolate postpartum***
- In a pregnant patient with **Class IV Lupus Nephritis**, the combination of **prednisone** and **azathioprine** is the safest evidence-based regimen to control active disease while protecting the fetus.
- **Azathioprine** is the preferred steroid-sparing agent during pregnancy because, unlike other immunosuppressants, the fetal liver lacks the enzyme **thiopurine methyltransferase** to convert it into its active toxic metabolites.
*Begin cyclophosphamide induction followed by azathioprine maintenance*
- **Cyclophosphamide** is highly **teratogenic** and is associated with permanent infertility and fetal malformations, making it contraindicated in the first trimester.
- It is categorized as **FDA Category D/X**, posing a significant risk of **miscarriage** and congenital defects during organogenesis.
*Start high-dose prednisone and add mycophenolate mofetil*
- **Mycophenolate mofetil (MMF)** is strictly contraindicated in pregnancy due to its association with **MMF embryopathy**, including cleft lip/palate and ear deformities.
- Current guidelines require a **washout period** for MMF before conception due to its significant **teratogenic potential**.
*Recommend therapeutic abortion followed by standard cyclophosphamide protocol*
- This approach violates **patient autonomy**, as the patient has specifically expressed a desire to continue the pregnancy.
- Medical management with **pregnancy-compatible drugs** is a viable alternative to termination, even in the setting of severe **lupus flares**.
*Start rituximab as it has minimal placental transfer*
- While **Rituximab** (a monoclonal antibody) has limited placental transfer in the **first trimester**, there is insufficient long-term safety data regarding its use in early pregnancy.
- It is generally reserved for **refractory cases** and is not the first-line choice for managing **lupus nephritis** during gestation.
Question 4: A 50-year-old woman with rheumatoid arthritis refractory to methotrexate is being considered for rituximab therapy. Her labs show: positive rheumatoid factor, anti-CCP antibodies, normal CBC, and creatinine 1.1 mg/dL. Hepatitis panel shows: HBsAg negative, anti-HBs positive, anti-HBc positive, HBV DNA undetectable. Analyze her hepatitis status and determine the appropriate management before starting rituximab.
A. Check HCV antibodies before proceeding
B. Proceed with rituximab as HBsAg is negative
C. Start lamivudine only if HBV DNA becomes detectable
D. Defer rituximab and use alternative biologic agent
E. Start entecavir prophylaxis before and during rituximab therapy (Correct Answer)
Explanation: ***Start entecavir prophylaxis before and during rituximab therapy***
- The patient has **resolved hepatitis B infection** (HBsAg negative, anti-HBc positive, anti-HBs positive), which carries a high risk of **reactivation** when using potent B-cell depleting agents like **rituximab**.
- Current guidelines recommend prophylactic antiviral therapy with **entecavir** or **tenofovir** starting before immunosuppression and continuing for at least **12 months** after the last dose of rituximab.
*Check HCV antibodies before proceeding*
- While screening for **HCV** is part of a general pre-biologic workup, it does not address the immediate high risk of **HBV reactivation** posed by her serology.
- Unlike HBV, HCV does not typically undergo the same style of **viral reactivation** into acute liver failure during B-cell depletion.
*Proceed with rituximab as HBsAg is negative*
- Being **HBsAg negative** does not eliminate the risk of reactivation; the presence of **anti-HBc** indicates latent virus remains in the liver as **cccDNA**.
- **Rituximab** is categorized as a high-risk drug (>10% risk of reactivation), making prophylaxis mandatory regardless of the negative surface antigen.
*Start lamivudine only if HBV DNA becomes detectable*
- A "pre-emptive" strategy (monitoring DNA) is less effective than **prophylaxis** for high-risk patients on rituximab, as liver injury can occur before DNA is detected.
- **Lamivudine** is no longer the preferred agent due to a high rate of **viral resistance**; entecavir or tenofovir are the first-line choices.
*Defer rituximab and use alternative biologic agent*
- Rituximab is a highly effective treatment for **refractory rheumatoid arthritis**, and its use is not contraindicated if proper **antiviral prophylaxis** is provided.
- Other biologics like TNF-inhibitors also carry reactivation risks (though lower), so checking and managing HBV status would still be required.
Question 5: A 38-year-old kidney transplant recipient on sirolimus develops progressive dyspnea. CT chest shows bilateral interstitial infiltrates and small pleural effusions. Bronchoscopy with BAL shows lymphocytic inflammation without organisms. Pulmonary function tests show restrictive pattern with reduced DLCO. Cardiac evaluation is normal. Analyze the clinical presentation to determine the most likely diagnosis and management.
A. Cytomegalovirus pneumonitis; start ganciclovir
B. Pneumocystis jirovecii pneumonia; start trimethoprim-sulfamethoxazole
C. Pulmonary edema from volume overload; increase diuretics
D. Acute cellular rejection affecting lungs; increase immunosuppression
E. Sirolimus-induced pneumonitis; discontinue sirolimus (Correct Answer)
Explanation: ***Sirolimus-induced pneumonitis; discontinue sirolimus***
- **Sirolimus (mTOR inhibitor)** is known to cause **interstitial pneumonitis**, presenting with progressive dyspnea, restrictive lung pattern, and **reduced DLCO**.
- The diagnosis is supported by a **lymphocytic BAL** that is negative for infectious organisms and symptoms that resolve upon **drug discontinuation**.
*Cytomegalovirus pneumonitis; start ganciclovir*
- CMV typically presents with **fever**, systemic symptoms, and specific cytology like **intranuclear inclusions** (owl's eyes) in BAL, which are absent here.
- The **lymphocytic inflammation** without organisms specifically points toward non-infectious drug toxicity rather than viral infection.
*Pneumocystis jirovecii pneumonia; start trimethoprim-sulfamethoxazole*
- PCP usually presents with significant **hypoxia** and a **diffuse ground-glass pattern** on CT, but BAL would typically show **cysts or trophozoites** with silver stain.
- Most transplant patients receive **prophylactic TMP-SMX**, and the sterile BAL in this patient makes an infectious fungal etiology unlikely.
*Pulmonary edema from volume overload; increase diuretics*
- While bilateral infiltrates and effusions occur in volume overload, the **normal cardiac evaluation** and sterile lymphocytic BAL argue against hydrostatic edema.
- Volume overload would not typically cause a marked **reduction in DLCO** or lymphocytic inflammation in the bronchoalveolar lavage fluid.
*Acute cellular rejection affecting lungs; increase immunosuppression*
- **Acute cellular rejection** in this context would apply to the transplanted organ (kidney), not the lungs, as this is a **kidney transplant recipient**.
- Increasing immunosuppression would be contraindicated if the underlying cause is **drug toxicity** from the current immunosuppressive regimen (sirolimus).
Question 6: A 42-year-old heart transplant recipient on cyclosporine, azathioprine, and prednisone develops pancytopenia (WBC 2,000/μL, hemoglobin 8.5 g/dL, platelets 75,000/μL). He recently started allopurinol for gout. Bone marrow biopsy shows hypocellularity without malignant cells. His renal function is normal. Analyze the most likely cause of his pancytopenia and determine appropriate management.
A. Prednisone-induced bone marrow suppression; reduce steroid dose
B. Cyclosporine toxicity; reduce dose and monitor levels
C. Post-transplant lymphoproliferative disorder; reduce immunosuppression
D. CMV infection; start ganciclovir therapy
E. Azathioprine-allopurinol interaction; discontinue allopurinol (Correct Answer)
Explanation: ***Azathioprine-allopurinol interaction; discontinue allopurinol***
- **Allopurinol** inhibits the enzyme **xanthine oxidase**, which is essential for the metabolism of **6-mercaptopurine** (the active metabolite of azathioprine), leading to toxic accumulation and severe **myelosuppression**.
- The sudden onset of **pancytopenia** following the addition of allopurinol to an azathioprine regimen is a classic medical emergency requiring immediate cessation of the offending agent or a 75% dose reduction of azathioprine.
*Prednisone-induced bone marrow suppression; reduce steroid dose*
- **Prednisone** typically causes **leukocytosis** (specifically neutrophilia) rather than pancytopenia.
- **Glucocorticoids** are not associated with direct bone marrow suppression at standard clinical doses.
*Cyclosporine toxicity; reduce dose and monitor levels*
- **Cyclosporine** toxicity primarily causes **nephrotoxicity**, hypertension, and gingival hyperplasia rather than severe hematologic toxicity.
- While it can be associated with minor anemia, it does not cause the profound **hypocellular bone marrow** seen in this patient.
*Post-transplant lymphoproliferative disorder; reduce immunosuppression*
- **PTLD** usually presents with **lymphadenopathy**, fever, and weight loss, and bone marrow biopsy would typically show **malignant cells** or B-cell proliferation.
- This patient's marrow is notably **hypocellular** without malignancy, making a drug-drug interaction much more probable.
*CMV infection; start ganciclovir therapy*
- **Cytomegalovirus (CMV)** infection can cause cytopenias, but it is usually accompanied by **systemic symptoms** like fever, malaise, or organ-specific findings like hepatitis.
- The **temporal relationship** between starting allopurinol and the rapid decline in blood counts point specifically to metabolic inhibition of azathioprine.
Question 7: A 28-year-old woman with systemic lupus erythematosus on chronic cyclophosphamide therapy presents with painless hematuria. Urinalysis shows 50-100 RBCs/hpf without casts. Urine cytology reveals atypical cells. Cystoscopy shows diffuse bladder wall erythema and hemorrhage. She has received cumulative cyclophosphamide dose of 60 grams over 3 years. Apply your knowledge to determine the most likely complication and appropriate next step.
A. Bladder transitional cell carcinoma; refer for oncology evaluation (Correct Answer)
B. Lupus cystitis; increase corticosteroid dose
C. Glomerulonephritis; perform kidney biopsy
D. Bacterial cystitis; treat with antibiotics and continue cyclophosphamide
E. Hemorrhagic cystitis; switch to mycophenolate and mesna prophylaxis
Explanation: ***Bladder transitional cell carcinoma; refer for oncology evaluation***
- Chronic exposure to the **cyclophosphamide** metabolite **acrolein** significantly increases the risk of **bladder malignancy**, especially when the cumulative dose exceeds **50 grams**.
- The presence of **painless hematuria**, **atypical cells on cytology**, and abnormal cystoscopy findings in this clinical context necessitates an urgent **oncological evaluation**.
*Lupus cystitis; increase corticosteroid dose*
- This is a rare manifestation of **SLE** characterized by gastrointestinal symptoms and **small-capacity bladder**, which does not align with chronic drug toxicity findings.
- Increasing steroids would be inappropriate as it doesn't address the high risk of **secondary malignancy** from cumulative drug exposure.
*Glomerulonephritis; perform kidney biopsy*
- This typically presents with **dysmorphic RBCs** or **RBC casts** and significant proteinuria, which are absent in this patient's urinalysis.
- The hematuria here is derived from the **bladder wall** as evidenced by the cystoscopy and atypical cytology, making a kidney biopsy unnecessary.
*Bacterial cystitis; treat with antibiotics and continue cyclophosphamide*
- Patients with bacterial cystitis usually present with **dysuria**, frequency, and **pyuria**, rather than painless hematuria with atypical cytology.
- Continuing cyclophosphamide would be dangerous given the high cumulative dose and evidence suggestive of **urothelial transformation**.
*Hemorrhagic cystitis; switch to mycophenolate and mesna prophylaxis*
- While **acrolein** causes hemorrhagic cystitis, the focal finding of **atypical cells** on cytology points toward **transitional cell carcinoma** rather than just inflammation.
- **Mesna** is used as a preventative agent to neutralize acrolein but is not a treatment for existing **malignant changes** or atypical cytology.
Question 8: A 55-year-old liver transplant recipient maintained on tacrolimus develops new-onset diabetes requiring insulin. He also has hypertension, chronic kidney disease (GFR 45 mL/min), and gingival hyperplasia. His current tacrolimus level is therapeutic. Apply pharmacologic principles to determine the most appropriate modification of his immunosuppressive regimen.
A. Switch from tacrolimus to mycophenolate monotherapy
B. Switch from tacrolimus to cyclosporine
C. Continue current regimen and optimize diabetes management
D. Add azathioprine and discontinue tacrolimus
E. Add sirolimus and reduce tacrolimus dose (Correct Answer)
Explanation: ***Add sirolimus and reduce tacrolimus dose***
- Adding an **mTOR inhibitor** like **sirolimus** allows for a significant reduction in the **calcineurin inhibitor (CNI)** dose, which helps mitigate **nephrotoxicity** and **post-transplant diabetes mellitus (PTDM)**.
- This strategy maintains effective **immunosuppression** while minimizing the metabolic and renal side effects directly caused by high levels of **tacrolimus**.
*Switch from tacrolimus to mycophenolate monotherapy*
- **Mycophenolate mofetil** as a monotherapy is generally insufficient to prevent **graft rejection** in liver transplant recipients.
- Removing the **calcineurin inhibitor** entirely poses a high risk of **acute cellular rejection** and is not standard clinical practice.
*Switch from tacrolimus to cyclosporine*
- **Cyclosporine** is associated with a higher incidence of **gingival hyperplasia** and **hirsutism**, which would likely worsen the patient's existing symptoms.
- Like tacrolimus, cyclosporine is a **calcineurin inhibitor** that carries risks of **nephrotoxicity** and **hypertension**, providing no significant advantage for his **CKD**.
*Continue current regimen and optimize diabetes management*
- While glucose control is important, ignoring the **iatrogenic cause** (tacrolimus) of **PTDM** and **nephrotoxicity** neglects the underlying pharmacological triggers.
- Failure to adjust the **tacrolimus dose** in a patient with **chronic kidney disease** and worsening metabolic profile increases the risk of long-term **graft failure** and cardiovascular complications.
*Add azathioprine and discontinue tacrolimus*
- **Azathioprine** is not potent enough to serve as the primary maintenance agent in the absence of a **calcineurin inhibitor** or **mTOR inhibitor**.
- Discontinuing tacrolimus abruptly without a robust alternative would lead to an unacceptably high risk of **allograft rejection**.
Question 9: A 32-year-old man with newly diagnosed Crohn's disease has severe perianal fistulizing disease. His gastroenterologist plans to start infliximab therapy. The patient's PPD test is 12 mm induration, chest X-ray shows calcified granuloma in the right upper lobe, and interferon-gamma release assay is positive. He has no symptoms of active tuberculosis. Apply current guidelines to determine the appropriate management before starting infliximab.
A. Complete 9 months of isoniazid before starting infliximab
B. Start infliximab immediately as chest X-ray shows old healed TB
C. Begin isoniazid prophylaxis concurrent with infliximab initiation (Correct Answer)
D. Start isoniazid and rifampin for 4 months before infliximab
E. Begin isoniazid prophylaxis for 1 month, then start infliximab
Explanation: ***Begin isoniazid prophylaxis concurrent with infliximab initiation***
- In patients with severe **fistulizing Crohn's disease** and **latent tuberculosis**, treatment for the underlying disease should not be delayed by months if the clinical situation is urgent.
- Guidelines allow for the initiation of **TNF-alpha inhibitors** like **infliximab** concurrently with, or shortly after starting, **isoniazid (INH)**, provided active TB has been ruled out by a normal **chest X-ray** and lack of symptoms.
*Complete 9 months of isoniazid before starting infliximab*
- Waiting for the full course of **INH** to be completed would cause an unnecessary and potentially dangerous delay in treating the patient's **severe Crohn's disease**.
- Evidence suggests that the risk of **TB reactivation** is significantly mitigated as soon as prophylaxis is established, making a 9-month delay non-standard.
*Start infliximab immediately as chest X-ray shows old healed TB*
- A **positive IGRA** and **PPD** indicate **latent tuberculosis infection (LTBI)**, regardless of whether the chest X-ray shows old granulomatous changes.
- **TNF-alpha inhibitors** carry a high risk of **reactivating TB**; starting them without any prophylaxis in a latent case is contraindicated.
*Start isoniazid and rifampin for 4 months before infliximab*
- While a 4-month course of **rifampin** or combination therapy is an option for **LTBI**, it is not a prerequisite to finish the entire course before starting biologic therapy.
- Delaying treatment for 4 months for a patient with **perianal fistulizing disease** could lead to clinical worsening, such as abscess formation or sepsis.
*Begin isoniazid prophylaxis for 1 month, then start infliximab*
- While starting **INH** for one month prior to biologics is a common strategy in stable patients, guidelines permit **concurrent initiation** in severe or urgent cases.
- In this scenario, the severity of the **fistulizing disease** prioritizes immediate intervention over the traditional 1-month wait period.
Question 10: A 45-year-old woman undergoes kidney transplantation and is started on tacrolimus, mycophenolate mofetil, and prednisone. Three weeks post-transplant, she develops tremors, elevated creatinine (2.8 mg/dL from baseline 1.2 mg/dL), and her tacrolimus trough level is 18 ng/mL (target 10-12 ng/mL). She recently started taking fluconazole for oral candidiasis. Apply your understanding of drug interactions to determine the most appropriate management.
A. Discontinue fluconazole and start caspofungin
B. Reduce tacrolimus dose and monitor levels closely (Correct Answer)
C. Increase mycophenolate dose to compensate
D. Add diltiazem to reduce tacrolimus metabolism
E. Discontinue tacrolimus and switch to cyclosporine
Explanation: ***Reduce tacrolimus dose and monitor levels closely***
- Fluconazole is a potent **CYP3A4 inhibitor** that decreases the metabolism of **tacrolimus**, leading to toxic accumulation and causing the observed **nephrotoxicity** (elevated creatinine) and **neurotoxicity** (tremors).
- The standard management of this drug-drug interaction is a **preemptive dose reduction** of tacrolimus while maintaining close monitoring of **trough levels** to ensure they return to the target therapeutic range.
*Discontinue fluconazole and start caspofungin*
- While caspofungin has fewer interactions, it is typically reserved for **invasive candidiasis** and is unnecessarily aggressive and expensive for treating simple **oral candidiasis**.
- Replacing the antifungal does not immediately address the current **supratherapeutic tacrolimus levels** already present in the patient's system.
*Increase mycophenolate dose to compensate*
- Increasing **mycophenolate mofetil** does nothing to treat **calcineurin inhibitor (CNI) toxicity** and may increase the risk of adverse effects like **bone marrow suppression**.
- Adjusting immunosuppression doses should be based on therapeutic monitoring and specific toxicity profiles rather than arbitrary compensation.
*Add diltiazem to reduce tacrolimus metabolism*
- Diltiazem is also a **CYP3A4 inhibitor**; adding it would further increase tacrolimus levels and worsen the patient's **acute kidney injury** and tremors.
- This strategy is sometimes used to lower drug costs in stable patients, but it is **contraindicated** in the setting of active drug toxicity.
*Discontinue tacrolimus and switch to cyclosporine*
- Since **cyclosporine** is also a calcineurin inhibitor and a substrate for **CYP3A4**, it would be subject to the same interaction with fluconazole.
- Switching agents is unnecessary and increases the risk of **graft rejection** when the issue is a manageable pharmacokinetic interaction.
